Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Capadenoson (BAY68-4986)
Capadenoson · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Capadenoson (BAY68-4986) | DRUG | 4 mg BAY68-4986 for five days |
Inclusion Criteria: * Male and/or female (without childbearing potential) white patients * History of persistent or permanent atrial fibrillation * 18 to 75 years of age Exclusion Criteria: * Patients with high-risk cardiovascular diseases * Stroke or myocardial infarction * Relevant pathological...
Top 5 of 17 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 3 | PHASE3 | REGN7508, REGN9933 |
| Johnson & Johnson | JNJ | 14 | PHASE3 | Milvexian |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Abelacimab, PKN605 |
| Milestone Pharmaceuticals, Inc. | MIST | 1 | PHASE3 | Etripamil |
| Bayer | BAYRY | 1 | PHASE2 | BAY 3670549 |
Capadenoson is an investigational small molecule being studied for atrial fibrillation, a common heart rhythm disorder. It was evaluated in a Phase 2 study of patients with persistent or permanent atrial fibrillation, where the objective was to investigate its effect on ventricular heart rate. It is not an approved therapy.
Capadenoson targets ADORA1, the adenosine A1 receptor, and acts as a partial agonist at that receptor. This receptor is involved in regulating heart rate and electrical conduction in the heart, which is the basis for studying the drug in atrial fibrillation.
Capadenoson is developed by Bayer AG, which trades on the OTC market under the ticker BAYRY. Bayer sponsored the clinical research conducted on the compound.
Capadenoson is in Phase 2 development. It is an investigational drug and has not been approved by the FDA for any indication. The completed Phase 2 trial enrolled 28 patients with atrial fibrillation in Germany.
Capadenoson has been studied in one clinical trial, NCT00568945, titled a study to investigate the effect of the A1 agonist Capadenoson on ventricular heart rate in patients with persistent or permanent atrial fibrillation. That Phase 2 trial is completed and enrolled 28 patients in Germany.
Yes. Capadenoson is also known as BAY68-4986, which is Bayer's internal compound designation for the same investigational drug. Both names refer to the same adenosine A1 receptor partial agonist studied in atrial fibrillation.